Rising Global Menopausal Population & Aging Female Population
The increase in the menopausal population is driven primarily by aging population worldwide. According to the World Health Organization (WHO), the number of people aged 60 and older is expected to reach 1.4 billion by 2030, with women making up the majority of this group due to longer life expectancy. As women live longer, the number of postmenopausal women typically aged 50 and above continues to grow, leading to a higher prevalence of menopause-related symptoms. For instance, the United Nations reports that countries like Japan (29.8%) and Italy (24.5%) have the highest proportions of elderly citizens, significantly increasing the demand for menopausal healthcare.
Vasomotor symptoms are the most common complaint during menopause, affecting approximately 75% to 80% of women in Western societies, according to The Menopause Society (formerly NAMS). These symptoms can significantly impair quality of life, leading to chronic sleep disturbances, mood changes, and a heightened risk for osteoporosis and cardiovascular disease due to estrogen decline. The aging female population also correlates with rising awareness; in the U.S., the National Institutes of Health (NIH) reports that approximately 1.3 million women reach menopause annually, which averages to about 3,500 to 4,000 women daily.
Additionally, cultural factors heavily influence symptom reporting and treatment-seeking behaviors; while Western societies show higher rates of medical intervention, many women globally still lack access to care. Notably, the growth of the aging population is prompting healthcare systems to prioritize menopause management, including hormone therapy and FDA-approved non-hormonal treatments, to address the increasing demand. Overall, as the female demographic continues to age globally, the prevalence of vasomotor symptoms will remain a major public health priority, emphasizing the need for improved research and accessible management options.
High Prevalence of Vasomotor Symptoms
The high prevalence of vasomotor symptoms, including hot flashes and night sweats, is a significant driver of the global menopause-related treatment. According to The Menopause Society (formerly NAMS), approximately 75% to 80% of women experience hot flashes during menopause, with about 25% reporting moderate-to-severe symptoms that significantly impact daily life. These symptoms typically commence during perimenopause and can persist for several years; the landmark SWAN study (Freeman et al., 2014) established that the median duration for frequent VMS is 7.4 years, though for many it can exceed a decade. This widespread nature of VMS is driven by hormonal fluctuations, primarily declining estrogen levels, which disrupt the thermoregulatory center in the hypothalamus.
In regions like North America and Europe, increased awareness and an aging female population contribute to higher diagnosis rates. According to the United Nations and WHO, the global population of women aged 50 and above is expected to reach approximately 1.2 billion by 2030, a demographic shift that fuels the demand for effective management. Additionally, a societal shift toward open discussions about women's health has led to more proactive healthcare-seeking behavior.
The treatment landscape has expanded significantly to include both hormonal and non-hormonal therapies. While the FDA approved Brisdelle (paroxetine) in 2013 as the first non-hormonal option for VMS, recent breakthroughs have introduced even more targeted treatments. For example, in 2023, the FDA approved Veozah (fezolinetant), a novel NK3 receptor antagonist that specifically targets the neural pathways causing hot flashes without using hormones. Overall, the persistent nature of VMS, coupled with these demographic trends and medical innovations, firmly positions the VMS segment as a primary catalyst for growth in the global women’s health market.
Approval & Launch of Novel Non-Hormonal Neurokinin Receptor Antagonists
The approval and subsequent launch of novel non-hormonal neurokinin-3 (NK3) receptor antagonists have significantly advanced the management of menopause-related vasomotor symptoms (VMS), such as hot flashes and night sweats. Traditionally, hormone replacement therapy (HRT) has been the primary treatment, but concerns regarding its associated risks including increased chances of breast cancer, cardiovascular events, and thromboembolism have driven the search for safer alternatives. On May 12, 2023, the U.S. Food and Drug Administration (FDA) approved fezolinetant (brand name Veozah), marking a historic milestone as the first-in-class non-hormonal treatment for moderate to severe VMS.
Fezolinetant works by selectively blocking neurokinin B (NKB) binding on the KNDy neurons in the hypothalamus, which are directly implicated in the thermoregulatory dysfunction that causes hot flashes. Because it is non-hormonal, it avoids the side effects typically associated with estrogen-based therapies. Its approval was supported by the SKYLIGHT 1 and 2 pivotal trials, which demonstrated significant reductions in hot flash frequency and severity with many women experiencing up to a 75% reduction in symptoms compared to placebo by week 12.
The introduction of these agents is rapidly expanding global treatment options, particularly for women who have contraindications to hormone therapy. Following its U.S. launch, Veozah gained approval in the European Union (December 2023) and became available in Canada (March 2025). With menopause affecting nearly half the global female population, these targeted NK3 receptor antagonists are fueling significant market growth by providing a safer, effective alternative for millions of women worldwide.
Strong Clinical Effectiveness of Hormone Therapy
Hormone therapy (HT), primarily involving estrogen and progesterone, remains a cornerstone in managing menopause-related vasomotor symptoms (VMS) such as hot flashes and night sweats. Its clinical effectiveness is well-established, with numerous studies demonstrating significant symptom relief. For instance, the Women's Health Initiative (WHI) trial, although initially highlighting some risks, also confirmed that estrogen therapy effectively reduces VMS severity and frequency in menopausal women. A meta-analysis published in the Cochrane Database of Systematic Reviews (2019) further supports this, indicating that estrogen therapy can alleviate hot flashes in approximately 75-80% of women, often within weeks of initiation.
Advances in hormone formulations and delivery methods have enhanced safety profiles and efficacy. Transdermal estrogen, for example, has been shown to offer effective symptom control with a lower risk of thromboembolic events compared to oral formulations, according to the Journal of the American Medical Association (JAMA). Moreover, the North American Menopause Society (NAMS) emphasizes that hormone therapy remains the most effective treatment for moderate to severe vasomotor symptoms when initiated near menopause onset, with benefits outweighing risks in healthy women.
News reports highlight increased awareness and acceptance of HT, driven by improved safety data and personalized medicine approaches. The 2022 North American Menopause Society guidelines reaffirm that hormone therapy is a first-line treatment for VMS, reinforcing its clinical dominance. This strong evidence base and evolving clinical guidelines have cemented hormone therapy as a primary driver of the global menopause-related VMS market.
In conclusion, the robust clinical effectiveness of hormone therapy, supported by extensive research and improved safety profiles, continues to propel its widespread adoption. As more women seek relief from menopausal symptoms, HT remains pivotal in the global market, driven by its proven efficacy and evolving clinical acceptance.
